Your immune systems best defense when it matters most
Subclinical hepatic encephalopathy impairs daily functioning
On October 4, 2016, Alnylam Pharmaceuticals terminated revusiran, its RNAi therapeutic for Transthyretin amyloidosis with cardiomyopathy, following 19 patient fatalities in a phase 3 trial,, 17 in the treatment cohort compared to 2 in the placebo group,, resulting in a $3.6 billion decline in market capitalization and investor doubt regarding the RNAi platform
Gallbladder events rise modestly, especially with rapid loss. Less common signals include skin dysesthesia, which is now on the label, and a small thyroid-cancer association in two population studies with a tiny absolute event rate. Depression and suicidality remain unproven
When Love Ends: Finding Yourself Again After a Breakup You can do everything right, communicate, put in the effort, show up, and it still doesnt turn out how you hoped
Vitamin B12, B6, or folate and cognitive function in community-dwelling older adults: a systematic review and meta-analysis